_id Chemical PMID Author, year Study type Species/cell type Measurement Timepoint Effect measure Outcome Lower Upper Unit Remarks 1 1-Ethyl-3-methylimidazolium diethylphosphate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 2.11 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 2 1-Ethyl-3-methylimidazolium diethylphosphate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 0.200507006601622 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 3 1-Ethyl-3-methylimidazolium diethylphosphate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 1.47408157603184 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 4 1-Ethyl-3-methylimidazolium diethylphosphate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 1.5579581982601103 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 5 2-Ethylhexyl diphenyl phosphate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 1.04 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 6 2-Ethylhexyl diphenyl phosphate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 4.725763568287641 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 7 2-Ethylhexyl diphenyl phosphate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 0.952046720545135 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 8 2-Ethylhexyl diphenyl phosphate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 1.00313766803373 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 9 2,2’,4,4’-Tetrabromodiphenyl ether 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 16.43 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 10 2,2’,4,4’-Tetrabromodiphenyl ether 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 37.47275749468281 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 11 2,2’,4,4’-Tetrabromodiphenyl ether 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 4.379233356637162 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 12 2,2’,4,4’-Tetrabromodiphenyl ether 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 0.820807195506619 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 13 3,3',5,5'-tetrabromobisphenol A 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 21.99 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 14 3,3',5,5'-tetrabromobisphenol A 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 3.7178748024825206 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 15 3,3',5,5'-tetrabromobisphenol A 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 4.373443185166591 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 16 3,3',5,5'-tetrabromobisphenol A 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 22.995461338703304 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 17 3,3',5,5'-tetrabromobisphenol A 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.31 1.62 4.69000000000000039079850466805510222911834716796875 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 18 5-Fluorouracil 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 19 5-Fluorouracil 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 20 5-Fluorouracil 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 21 5-Fluorouracil 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 22 5-Fluorouracil 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.94 1.21 52.7000000000000028421709430404007434844970703125 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 23 5-Fluorouracil 21328588 Mandenius, 2011 in vitro HL-1 Respiration "" EC50 0.36 0.25 0.5 µM "" 24 5-Fluorouracil 25034007 Eskandari, 2014 in vitro ARVMs Cell viability 2h IC50 15.0 "" µM "" 25 5-Fluorouracil 24704391 Lamberti, 2014 in vitro H9c2 Cell viability 72h IC50 400.0 "" µM "" 26 5-Fluorouracil 25671635 Focaccetti, 2015 in vitro HCMs Cell viability 72h IC50 4.866 "" µM "" 27 5-Fluorouracil 35101590 Li, 2022 in vitro H9c2 Cell viability 48h IC50 5.0 "" µM "" 28 Aconitine 30410440 Ma, 2018 in vitro H9c2 Cell viability 24h IC50 32.0 "" µM "" 29 Aconitine 31975431 Li, 2020 in vivo Zebrafish Mortality 48h LD50 7.92 6.49 9.8300000000000000710542735760100185871124267578125 µM "" 30 Aconitine 31975431 Li, 2020 in vitro H9c2 Cell viability 30m IC50 4.411 3.68 5.589999999999999857891452847979962825775146484375 mM "" 31 Aconitine 18779382 Wang, 2008 in vitro H9c2 Kv2.1 "" IC50 1.4 "" µM "" 32 Aconitine 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 0.03 "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 33 Aconitine 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 (↑) 0.01  "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 34 Amitriptyline 25237062 Scott, 2014 in vitro hiPSC-CMs Peak amplitude "" IC50 6.65 "" µM Decrease in amplitude 35 Amitriptyline 25237062 Scott, 2014 in vitro hiPSC-CMs Beat rate "" IC50 6.78 "" µM Decrease in beat rate 36 Amitriptyline 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ peak count "" IC50 0.488109566666667 0.22 0.6999999999999999555910790149937383830547332763671875 µM Peak count: number of contractions over a period of time. 37 Amitriptyline 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient width "" IC50 0.630555512192637 0.26 0.9899999999999999911182158029987476766109466552734375 µM Width of the calcium transient 38 Amitriptyline 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient amplitude "" IC50 0.489935966666667 0.24 0.68000000000000004884981308350688777863979339599609375 µM Peak amplitude of the calcium peak as measurement for contractility 39 Amitriptyline 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient rise time "" IC50 0.7650458001160785 0.45 0.9499999999999999555910790149937383830547332763671875 µM "" 40 Amitriptyline 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient decay time "" IC50 0.5265346341388603 0.31 0.75 µM "" 41 Amitriptyline 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient spacing "" IC50 0.36593444453326907 0.16 0.560000000000000053290705182007513940334320068359375 µM "" 42 Amitriptyline 28069985 Pointon, 2017 in vitro 3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs) Peak count "" IC50 4.9971560266446 1.018569383524945 µM Peak count: number of contractions over a period of time. 43 Amitriptyline 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.9 2.14 3.970000000000000195399252334027551114559173583984375 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 44 Amitriptyline 27130441 Stoetzer, 2016 in vitro NRVMs Nav1.5 "" IC50 13.0 12.0 14 µM "" 45 Amitriptyline 29239964 Tsujikawa, 2018 in vitro Guinea pig CMs Sodium current "" IC50 0.39 "" µM "" 46 Amitriptyline 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 > 30  "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 47 Amitriptyline 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 3.0 "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 48 Amsacrine 1958848 Dorr, 1991 in vitro NRCMs Cell viability 3-6h IC50 30.0 "" µg/(ml h) "" 49 Anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 9.13 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 50 Anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 51 Anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 52 Anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 18.41468005066611 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 53 Anthracene 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.31 1.16 12.300000000000000710542735760100185871124267578125 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 54 Arsenic trioxide 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 3.0 "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 55 Arsenic trioxide 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 1.0 "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 56 Benz(a)anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 10.78 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 57 Benz(a)anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 58 Benz(a)anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 61.0621878095161 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 59 Benz(a)anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 0.348807682728123 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 60 Benz(a)anthracene 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.57 1.2 13.199999999999999289457264239899814128875732421875 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 61 Benzo(a)pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 1.43 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 62 Benzo(a)pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 63 Benzo(a)pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 42.98451393910572 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 64 Benzo(a)pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 2.30172365931584 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 65 Benzo(e)pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 8.32 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 66 Benzo(e)pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 67 Benzo(e)pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 56.156909284493615 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 68 Benzo(e)pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 6.957456397836642 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 69 Benzo(e)pyrene 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.44 1.18 11.800000000000000710542735760100185871124267578125 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 70 Benzo(e)pyrene 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.77 1.2 18 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 71 Berberine chloride 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 6.24 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 72 Berberine chloride 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 0.59768133641112 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 73 Berberine chloride 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 0.07024175002302288 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 74 Berberine chloride 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 0.01146528847415449 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 75 Berberine chloride 29233041 Zhang, 2018 in vitro NRCMs Peak amplitude 1.5h IC50 2.1 "" µM "" 76 Berberine chloride 16424781 Menchaca, 2006 in vitro HEK-293 hERG "" IC50 3.1 "" µM "" 77 Bisphenol A 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 78 Bisphenol A 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 27.303798623491115 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 79 Bisphenol A 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 3.8649802059351606 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 80 Bisphenol A 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 81 Bisphenol A 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 13.7 5.28 51.2000000000000028421709430404007434844970703125 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 82 Bisphenol A 34419494 Hyun, 2021 in vitro hiPSC-CMs Ca2+ current "" IC50 6.9 5.800000000000001 8 µM "" 83 Bisphenol A 34419494 Hyun, 2021 in vitro hiPSC-CMs Na+ current "" IC50 56.5 38.6 74.400000000000005684341886080801486968994140625 µM "" 84 Bortezomib 23315586 Pointon, 2013 in vitro hESC-CMs ATP "" IC50 0.005 0.004 0.005000000000000000104083408558608425664715468883514404296875 µM ATP as measurement for mitochondrial dysfunction 85 Bortezomib 23315586 Pointon, 2013 in vitro hESC-CMs ΔΨm "" IC50 0.006 0.005 0.00600000000000000012490009027033011079765856266021728515625 µM ΔΨm: mitochondrial membrane potential 86 Bortezomib 23315586 Pointon, 2013 in vitro hESC-CMs Ca2+ mobilization "" IC50 0.06 0.059 0.059999999999999997779553950749686919152736663818359375 µM Inhibition of Ca2+ mobilization compared to control 87 Bortezomib 23315586 Pointon, 2013 in vitro hESC-CMs ER integrity "" IC50 86.9 86.32 87.469999999999998863131622783839702606201171875 µM Measured with ER Tracker (imaging) 88 Bortezomib 28546047 Koci, 2017 in vitro hiPSC-CMs Beat rate "" 20% change 0.3 "" µM "" 89 Bortezomib 28546047 Koci, 2017 in vitro hiPSC-CMs Cell viability 72h 20% decrease 1.0 "" µM "" 90 Cadmium (Cd2+) 34255886 Haverinen, 2021 in vitro Rainbow trout CMs Ca2+ current "" IC50 0.98 "" µM L-type Ca2+ current (ICaL) 91 Cadmium (Cd2+) 34255886 Haverinen, 2021 in vitro Rainbow trout CMs Na+ current "" IC50 261.3 188.10000000000002 334.5 µM "" 92 Carbachol 11750078 Howard, 2002 in vitro Rat cardiac membrane Muscarinic receptor binding "" IC50 7.0 4.0 12 nM Adult rat cardiac membrane 93 Carbachol 11750078 Howard, 2002 in vitro Rat cardiac membrane Muscarinic receptor binding "" IC50 20.0 9.0 44 nM Neonatal rat cardiac membrane 94 Chlorpyrifos 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 95 Chlorpyrifos 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 47.62225939818692 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 96 Chlorpyrifos 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 12.384918691990402 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 97 Chlorpyrifos 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 22.57527340474811 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 98 Chlorpyrifos 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 7.04 3.37 23.699999999999999289457264239899814128875732421875 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 99 Chlorpyrifos 11750078 Howard, 2002 in vitro Rat cardiac membrane Muscarinic receptor binding "" IC50 7.0 "" nM Adult rat cardiac membrane 100 Chlorpyrifos 11750078 Howard, 2002 in vitro Rat cardiac membrane Muscarinic receptor binding "" IC50 15.0 "" nM Neonatal rat cardiac membrane 101 Chlorpyrifos-methyl 19674799 Tryfonos, 2009 in vitro Sparus aurata Contractility 30m IC50 93.7 89.7 97.900000000000005684341886080801486968994140625 µM "" 102 Cocaine 16406254 Ma, 2006 in vitro Guinea pig CMs Sodium current "" IC50 45.9 "" µM 15 μM suppressed AP upstroke velocity from ∼22 mV/ms to less than 5 mV/ms 103 Cresyl diphenyl phosphate (CDP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 1.12 "" µM "" 104 Daunorubicin 1958848 Dorr, 1991 in vitro NRCMs Cell viability 3-6h IC50 16.5 "" µg/(ml h) "" 105 Daunorubicin 21328588 Mandenius, 2011 in vitro HL-1 Respiration "" EC50 0.12 0.12 0.14000000000000001332267629550187848508358001708984375 µM Oxygen uptake rates, or respiration, provide direct information on the metabolic activity in cells and therefore on cellular homeostasis. 106 Daunorubicin 33719006 Bozza, 2021 in vitro hiPSC-CMs Cell viability 48h IC50 0.33 "" µM "" 107 Daunorubicin 21046361 Vavrova, 2011 in vitro H9c2 Cell viability 24h IC50 0.48 "" µM "" 108 Daunorubicin 17587482 Adamcova, 2007 in vitro NRVMs Cell viability 72h IC50 0.55 "" µM "" 109 Daunorubicin 31650569 Gwarda, 2019 in vitro H9c2 Cell viability 24h IC50 0.64 "" µM "" 110 Di(2-ethylhexyl)phthalate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 111 Di(2-ethylhexyl)phthalate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 112 Di(2-ethylhexyl)phthalate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 12.218047963208406 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 113 Di(2-ethylhexyl)phthalate 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 5.883878124999231 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 114 Di(2-ethylhexyl)phthalate 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 1000.0 1.53 457000 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 115 Diazinon 19674799 Tryfonos, 2009 in vivo Sparus aurata Contractility 30m IC50 164.0 458.0 170 µM "" 116 Dibenz(a,c)anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 117 Dibenz(a,c)anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 118 Dibenz(a,c)anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 119 Dibenz(a,c)anthracene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 11.9864929394371 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 120 Dibenz(a,c)anthracene 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 8.56 2.72 47.60000000000000142108547152020037174224853515625 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 121 Dieldrin 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 0.76 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 122 Dieldrin 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 0.21827059281214095 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 123 Dieldrin 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 1.07628932709562 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 124 Dieldrin 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 0.47321013894299896 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 125 Dieldrin 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.38 1.17 12.699999999999999289457264239899814128875732421875 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 126 Doxorubicin 23315586 Pointon, 2013 in vitro hESC-CMs ATP "" IC50 0.003 0.002 0.003000000000000000062450045135165055398829281330108642578125 µM ATP as measurement for mitochondrial dysfunction 127 Doxorubicin 23315586 Pointon, 2013 in vitro hESC-CMs ΔΨm "" IC50 10.6 10.52 10.6699999999999999289457264239899814128875732421875 µM ΔΨm: mitochondrial membrane potential 128 Doxorubicin 23315586 Pointon, 2013 in vitro hESC-CMs Ca2+ mobilization "" IC50 40.78 40.5 41.0499999999999971578290569595992565155029296875 µM Inhibition of Ca2+ mobilization compared to control 129 Doxorubicin 23315586 Pointon, 2013 in vitro hESC-CMs ER integrity "" IC50 >100 "" µM Measured with ER Tracker (imaging) 130 Doxorubicin 25237062 Scott, 2014 in vitro hiPSC-CMs Peak amplitude "" IC50 4.75 "" µM Decrease in amplitude 131 Doxorubicin 25237062 Scott, 2014 in vitro hiPSC-CMs Beat rate "" IC50 4.75 "" µM Decrease in beat rate 132 Doxorubicin 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ peak count "" IC50 >100 "" µM Peak count: number of contractions over a period of time. 133 Doxorubicin 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient width "" IC50 40.76670598599155 38.06 42.07000000000000028421709430404007434844970703125 µM Width of the calcium transient 134 Doxorubicin 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient amplitude "" IC50 >100 "" µM Peak amplitude of the calcium peak as measurement for contractility 135 Doxorubicin 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient rise time "" IC50 3.6320612638864014 2.14 5.12000000000000010658141036401502788066864013671875 µM "" 136 Doxorubicin 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient decay time "" IC50 13.885542841387224 3.38 23.449999999999999289457264239899814128875732421875 µM "" 137 Doxorubicin 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient spacing "" IC50 >100 "" µM "" 138 Doxorubicin 28069985 Pointon, 2017 in vitro 3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs) Peak count "" IC50 47.698821102022904 3.37782831788947 µM Peak count: number of contractions over a period of time. 139 Doxorubicin 35488128 Gryshovka, 2022 in vitro hiPSC-CMs Cell viability 24h IC50 3.0 "" µM "" 140 Doxorubicin 1958848 Dorr, 1991 in vitro NRCMs Cell viability 3-6h IC50 5.72 µg/(ml h) "" 141 Doxorubicin 28546047 Koci, 2017 in vitro hiPSC-CMs Beat rate "" 20% change 3.0 "" µM "" 142 Doxorubicin 28546047 Koci, 2017 in vitro hiPSC-CMs Cell viability 72h 20% decrease 3.0 "" µM "" 143 Doxorubicin 21328588 Mandenius, 2011 in vitro HL-1 Respiration "" EC50 0.43 0.38 0.5 µM "" 144 Doxorubicin 33719006 Bozza, 2021 in vitro hiPSC-CMs Cell viability 48h IC50 0.54 "" µM "" 145 Doxorubicin 28300219 Zhao, 2017 in vitro hiPSC-CMs Cell viability 48h IC50 3.5 "" µM "" 146 Doxorubicin 31650569 Gwarda, 2019 in vitro H9c2 Cell viability 24h IC50 0.65 "" µM "" 147 Doxorubicin 34525346 Magdy, 2021 in vitro hiPSC-CMs Cell viability 72h IC50 2.622 "" µM "" 148 Doxorubicin 34525346 Magdy, 2021 in vitro hiPSC-CMs Caspase 3/7 activity 24h EC50 2.078 "" µM "" 149 Doxorubicin 34525346 Magdy, 2021 in vitro hiPSC-CMs ROS 72h EC50 10.35 "" µM "" 150 Doxorubicin 31797733 Weng, 2020 in vitro Organ on chip incl. hiPSC-CMs Beat rate 48h IC50 0.04107 "" µM Normalized rate change (%), R2 = 0.79. 151 Doxorubicin 31797733 Weng, 2020 in vitro Organ on chip incl. hiPSC-CMs Beat rate 48h IC50 0.2298 "" µM Normalized Max. rate change (%), R2 = 0.82. 152 Doxorubicin 32185414 Karhu, 2020 in vitro hiPSC-CMs Cell viability 48h IC50 0.8 "" µM R2 = 0.83. 153 Doxorubicin 32185414 Karhu, 2020 in vitro NRVMs Cell viability 48h IC50 0.48 "" µM R2 = 0.98. 154 Doxorubicin 24704391 Lamberti, 2014 in vitro H9c2 Cell viability 72h IC50 0.12 "" µM "" 155 Doxorubicin 15273722 Kluza, 2004 in vitro H9c2 Cell viability 24h IC50 0.9 0.89 0.91000000000000003108624468950438313186168670654296875 µM "" 156 Doxorubicin 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 1.0 "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 157 Doxorubicin 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 10.0 "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 158 Endosulfan 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 3.81 2.3 7.21999999999999975131004248396493494510650634765625 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 159 5-Fluorouracil 23315586 Pointon, 2013 in vitro hESC-CMs ATP "" IC50 93.0 92.38 93.6099999999999994315658113919198513031005859375 µM ATP as measurement for mitochondrial dysfunction 160 5-Fluorouracil 23315586 Pointon, 2013 in vitro hESC-CMs ΔΨm "" IC50 0.09 0.089 0.0899999999999999966693309261245303787291049957275390625 µM ΔΨm: mitochondrial membrane potential 161 5-Fluorouracil 23315586 Pointon, 2013 in vitro hESC-CMs Ca2+ mobilization "" IC50 0.03 0.037 0.037999999999999999056310429068616940639913082122802734375 µM Inhibition of Ca2+ mobilization compared to control 162 5-Fluorouracil 23315586 Pointon, 2013 in vitro hESC-CMs ER integrity "" IC50 0.06 0.05 0.059999999999999997779553950749686919152736663818359375 µM Measured with ER Tracker (imaging) 163 5-Fluorouracil 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 > 30  "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 164 5-Fluorouracil 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 > 30  "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 165 Idarubicin 23315586 Pointon, 2013 in vitro hESC-CMs ATP "" IC50 0.13 0.12 0.13000000000000000444089209850062616169452667236328125 µM ATP as measurement for mitochondrial dysfunction 166 Idarubicin 23315586 Pointon, 2013 in vitro hESC-CMs ΔΨm "" IC50 0.013 0.012 0.01299999999999999940325512426397835952229797840118408203125 µM ΔΨm: mitochondrial membrane potential 167 Idarubicin 23315586 Pointon, 2013 in vitro hESC-CMs Ca2+ mobilization "" IC50 0.0134 0.0133 0.01340000000000000045241588253475129022262990474700927734375 µM Inhibition of Ca2+ mobilization compared to control 168 Idarubicin 23315586 Pointon, 2013 in vitro hESC-CMs ER integrity "" IC50 0.002 0.001 0.00200000000000000004163336342344337026588618755340576171875 µM Measured with ER Tracker (imaging) 169 Idarubicin 1958848 Dorr, 1991 in vitro NRCMs Cell viability 3-6h IC50 0.84 "" µg/(ml h) "" 170 Idarubicin 33719006 Bozza, 2021 in vitro hiPSC-CMs Cell viability 48h IC50 0.25 "" µM "" 171 Idarubicin 34787021 Zhang, 2021 in vitro hl-1 Cell viability 24h IC50 7.0 "" µM "" 172 Idarubicin 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 0.3 "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 173 Idarubicin 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 3.0 "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 174 Imatinib 23315586 Pointon, 2013 in vitro hESC-CMs ATP "" IC50 15.7 15.59 15.800000000000000710542735760100185871124267578125 µM ATP as measurement for mitochondrial dysfunction 175 Imatinib 23315586 Pointon, 2013 in vitro hESC-CMs ΔΨm "" IC50 26.0 25.82 26.1700000000000017053025658242404460906982421875 µM ΔΨm: mitochondrial membrane potential 176 Imatinib 23315586 Pointon, 2013 in vitro hESC-CMs Ca2+ mobilization "" IC50 20.4 20.26 20.530000000000001136868377216160297393798828125 µM Inhibition of Ca2+ mobilization compared to control 177 Imatinib 23315586 Pointon, 2013 in vitro hESC-CMs ER integrity "" IC50 52.0 51.65 52.340000000000003410605131648480892181396484375 µM Measured with ER Tracker (imaging) 178 Imatinib 35488128 Gryshovka, 2022 in vitro hiPSC-CMs Cell viability 24h IC20 30.0 "" µM "" 179 Imatinib 28315715 Chambers, 2017 in vitro H9c2 Cell viability 24h IC50 26.2 19.1 33.2999999999999971578290569595992565155029296875 µM "" 180 Imatinib 30910525 Burke, 2019 in vitro Rat CFs Cell viability 24h IC50 14.8 "" µM "" 181 Imatinib 30910525 Burke, 2019 in vitro Rat CFs Cell viability 48h IC50 11.0 "" µM "" 182 Imatinib 22641616 Hu, 2012 in vitro NRCMs ATP 24h LOAEL 12.5 "" µM Lowest dose that caused significant change from the vehicle control 183 Imatinib 22641616 Hu, 2012 in vitro NRCMs LDH 24h LOAEL 25.0 "" µM "" 184 Imatinib 22641616 Hu, 2012 in vitro NRCMs Caspase 3/7 activity 24h LOAEL 12.5 "" µM "" 185 Imatinib 22641616 Hu, 2012 in vitro NRCMs ΔΨm 24h LOAEL 25.0 "" µM "" 186 Imatinib 22641616 Hu, 2012 in vitro NRCMs XBP1 splicing 24h LOAEL 10.0 "" µM "" 187 Imatinib 22641616 Hu, 2012 in vitro NRCMs CHOP induction 24h LOAEL 10.0 "" µM "" 188 Imatinib 18664550 Will, 2008 in vitro H9c2 ATP 24h IC50 30.53 29.07 31.989999999999998436805981327779591083526611328125 µM Glucose containing media 189 Imatinib 18664550 Will, 2008 in vitro H9c2 ATP 24h IC50 29.17 27.4 30.940000000000001278976924368180334568023681640625 µM Galactose containing media 190 Imatinib 18664550 Will, 2008 in vitro H9c2 Complex 1 activity 24h IC50 >300 "" µM "" 191 Imatinib 18664550 Will, 2008 in vitro H9c2 Complex 5 activity 24h IC50 190.0 "" µM "" 192 Imatinib 35216404 Bouitbir, 2022 in vitro H9c2 ATP 24h IC50 19.5 "" µM Glucose containing media 193 Imatinib 35216404 Bouitbir, 2022 in vitro H9c2 ATP 24h IC50 22.3 "" µM Galactose containing media 194 Imatinib 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 30.0 "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 195 Imatinib 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 10.0 "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 196 Lead chloride 28836190 Mattos, 2017 in vivo Guinea pig heart Contractility "" IC50 55.0 "" µM Amplitude of contraction (tension in gf/cm2) 197 Lead chloride 28836190 Mattos, 2017 in vitro Guinea pig CMs Ca2+ current "" IC50 18.0 10.0 26 µM Cav1.2 channel (ICa) 198 Lindane 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 199 Lindane 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 12.142755544523702 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 200 Lindane 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 3.6574232703683207 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 201 Lindane 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 14.524658940031504 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 202 Lindane 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 5.72 1.89 4380 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 203 Loperamide 27530870 Kang, 2016 in vitro HEK-293 Nav1.5 "" IC50 297.0 "" nM Holding potential of -90 mV 204 Loperamide 27530870 Kang, 2016 in vitro HEK-293 Nav1.5 "" IC50 239.0 "" nM Holding potential of -70 mV 205 Loperamide 27530870 Kang, 2016 in vitro HEK-293 hERG "" IC50 89.0 "" nM Room temperature 206 Loperamide 27530870 Kang, 2016 in vitro HEK-293 hERG "" IC50 33.0 "" nM Physiological temperature 207 Mitomycin A 1458553 Dorr, 1992 in vitro NRCMs Cell viability 3h IC50 2.1 "" µM "" 208 Mitomycin C 1458553 Dorr, 1992 in vitro NRCMs Cell viability 3h IC50 >274 "" µM "" 209 Mitoxantrone 23315586 Pointon, 2013 in vitro hESC-CMs ATP "" IC50 0.4 0.39 0.40000000000000002220446049250313080847263336181640625 µM ATP as measurement for mitochondrial dysfunction 210 Mitoxantrone 23315586 Pointon, 2013 in vitro hESC-CMs ΔΨm "" IC50 3.2 3.17 3.220000000000000195399252334027551114559173583984375 µM ΔΨm: mitochondrial membrane potential 211 Mitoxantrone 23315586 Pointon, 2013 in vitro hESC-CMs Ca2+ mobilization "" IC50 3.3 3.27 3.319999999999999840127884453977458178997039794921875 µM Inhibition of Ca2+ mobilization compared to control 212 Mitoxantrone 23315586 Pointon, 2013 in vitro hESC-CMs ER integrity "" IC50 3.4 3.37 3.4199999999999999289457264239899814128875732421875 µM Measured with ER Tracker (imaging) 213 Mitoxantrone 1958848 Dorr, 1991 in vitro NRCMs Cell viability 3-6h IC50 4.0 "" µg/(ml h) "" 214 Mitoxantrone 28546047 Koci, 2017 in vitro hiPSC-CMs Beat rate "" 20% change 1.0 "" µM "" 215 Mitoxantrone 28546047 Koci, 2017 in vitro hiPSC-CMs Cell viability 72h 20% decrease 1.0 "" µM "" 216 Mitoxantrone 23261645 Schweikart, 2013 in vitro hiPSC-CMs Cell viability 1h IC50 127.0 "" µM "" 217 Mitoxantrone 23261645 Schweikart, 2013 in vitro hiPSC-CMs Cell viability 12h IC50 3.1 "" µM "" 218 Mitoxantrone 23261645 Schweikart, 2013 in vitro hiPSC-CMs Cell viability 72h IC50 0.5 "" µM "" 219 Mitoxantrone 23261645 Schweikart, 2013 in vitro hiPSC-CMs ATP 72h IC50 0.8 "" µM "" 220 Mitoxantrone 15273722 Kluza, 2004 in vitro H9c2 Cell viability 24h IC50 1.6 1.3 1.899999999999999911182158029987476766109466552734375 µM "" 221 Mitoxantrone 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 3.0 "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 222 Mitoxantrone 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 0.3 "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 223 Nifedipine 22972846 Sirenko, 2013 in vitro hiPSC-CMs Beat rate "" IC50 0.12 "" µM "" 224 Nifedipine 23315586 Pointon, 2013 in vitro hESC-CMs ATP "" IC50 >100 "" µM ATP as measurement for mitochondrial dysfunction 225 Nifedipine 23315586 Pointon, 2013 in vitro hESC-CMs ΔΨm "" IC50 >100 "" µM ΔΨm: mitochondrial membrane potential 226 Nifedipine 23315586 Pointon, 2013 in vitro hESC-CMs Ca2+ mobilization "" IC50 >100 "" µM Inhibition of Ca2+ mobilization compared to control 227 Nifedipine 23315586 Pointon, 2013 in vitro hESC-CMs ER integrity "" IC50 >100 "" µM Measured with ER Tracker (imaging) 228 Nifedipine 25219538 Gibson, 2014 in vitro hiPSC-CMs Ca2+ current "" IC50 0.039 "" µM After acute exposure 229 Nifedipine 25237062 Scott, 2014 in vitro hiPSC-CMs Peak amplitude "" IC50 7.37 "" µM Decrease in amplitude 230 Nifedipine 25237062 Scott, 2014 in vitro hiPSC-CMs Beat rate "" IC50 2.27 "" 42 in % of control because plateau was not reached, EC50 could not be calculated 231 Nifedipine 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ current "" IC50 0.93 "" µM Calcium channel inhibitor 232 Nifedipine 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ peak count "" IC50 0.933096566666667 0.38 1.7199999999999999733546474089962430298328399658203125 µM Peak count: number of contractions over a period of time. 233 Nifedipine 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient width "" IC50 1.2886851277115852 0.86 1.6999999999999999555910790149937383830547332763671875 µM Width of the calcium transient 234 Nifedipine 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient amplitude "" IC50 0.361144833333333 0.24 0.460000000000000019984014443252817727625370025634765625 µM Peak amplitude of the calcium peak as measurement for contractility 235 Nifedipine 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient rise time "" IC50 0.6551296611460257 0.4 0.8000000000000000444089209850062616169452667236328125 µM "" 236 Nifedipine 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient decay time "" IC50 1.4163737617107073 0.11 6.13999999999999968025576890795491635799407958984375 µM "" 237 Nifedipine 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient spacing "" IC50 0.2542488299647862 0.03 0.83999999999999996891375531049561686813831329345703125 µM "" 238 Nifedipine 28069985 Pointon, 2017 in vitro 3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs) Peak count "" IC50 0.034119446326348994 0.005484630147128975 µM Peak count: number of contractions over a period of time. 239 Nifedipine 31385592 Feric, 2019 in vitro 3D cardiac microtissue (hiPSC-CMs, cardiac fibroblasts) Contractility "" IC50 62.0 "" nM Change in contractile force 240 Nifedipine 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 20.8 8.7 67.400000000000005684341886080801486968994140625 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 241 Nifedipine 33813278 Lee, 2021 in vitro hiPSC-CMs Peak amplitude "" IC50 0.3 "" µM Parameter of contractile force. 242 Nifedipine 21328588 Mandenius, 2011 in vitro HL-1 Respiration "" EC50 >1000 "" µM "" 243 Nifedipine 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 > 3  "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 244 Nifedipine 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 (↑) 0.1  "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 245 Paraoxon 19674799 Tryfonos, 2009 in vivo Sparus aurata Contractility 30m IC50 3.2 3.17 3.319999999999999840127884453977458178997039794921875 µM "" 246 Parathion 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 15.09 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 247 Parathion 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 7.462307505897089 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 248 Parathion 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 3.58245730566495 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 249 Parathion 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 12.321953100837701 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 250 Parathion-methyl 19674799 Tryfonos, 2009 in vivo Sparus aurata Contractility 30m IC50 80.3 75.16 85.7000000000000028421709430404007434844970703125 µM "" 251 Permethrin 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 252 Permethrin 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 253 Permethrin 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 0.07997352002027538 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 254 Permethrin 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 0.337715562209982 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 255 Permethrin 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.49 1.21 12.5999999999999996447286321199499070644378662109375 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 256 Phenanthrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 257 Phenanthrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 33.29727119738452 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 258 Phenanthrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 8.049186382259762 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 259 Phenanthrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 22.17945338031911 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 260 Phenanthrene 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 37.5 4.08 836 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 261 Phenanthrene 33906022 Abramochkin, 2021 in vitro Navaga cod CMs K+ current "" IC50 1.95 1.85 2.04999999999999982236431605997495353221893310546875 µM Atrial Ikr potassium current 262 Phenanthrene 33906022 Abramochkin, 2021 in vitro Navaga cod CMs K+ current "" IC50 2.2 1.9 2.5 µM Ventricular Ikr potassium current 263 Pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 264 Pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean >100 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 265 Pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 2.1992719630538 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 266 Pyrene 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 4.0062179400930304 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 267 Pyrene 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 2.36 1.17 12.300000000000000710542735760100185871124267578125 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 268 Rosiglitazone 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 > 30  "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 269 Rosiglitazone 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 (↑)1  "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control. 270 Rosiglitazone 24249632 Mishra, 2014 in vitro H9c2 Cell viability 24h IC50 55.0 50.0 60 µM "" 271 Rosiglitazone 21774756 Szebeni, 2011 in vitro Canine VCMs Ito "" IC50 25.2 22.5 27.89999999999999857891452847979962825775146484375 µM Ito: Cardiac transient outward potassium current 272 Rosiglitazone 21774756 Szebeni, 2011 in vitro Canine VCMs Ikr "" IC50 72.3 63.0 81.599999999999994315658113919198513031005859375 µM Ikr: Rapid delayed rectifier potassium current 273 Rosiglitazone 21774756 Szebeni, 2011 in vitro Canine VCMs Ca2+ current "" IC50 82.5 73.1 91.900000000000005684341886080801486968994140625 µM "" 274 Sibutramine 18781376 Kim, 2009 in vitro HEK-293 hERG "" IC50 2.5 "" µM At -40 mV 275 Sibutramine 18829731 Kim, 2008 in vitro CHO cells hERG "" IC50 2.41 1.9 2.899999999999999911182158029987476766109466552734375 µg/mL "" 276 Sibutramine 18829731 Kim, 2008 in vitro ARVMs Na+ current "" IC50 7.72 5.98 9.46000000000000085265128291212022304534912109375 µg/mL "" 277 Sibutramine 18829731 Kim, 2008 in vitro ARVMs Ca2+ current "" IC50 2.79 2.32 3.2599999999999997868371792719699442386627197265625 µg/mL "" 278 Tebuconazole 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean >30 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 279 Tebuconazole 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 34.886491754886805 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 280 Tebuconazole 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 7.820019423184851 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 281 Tebuconazole 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 10.027007638969604 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 282 Tebuconazole 32798748 Othmene, 2020 in vitro H9c2 Cell viability 24h IC50 50.0 "" µM "" 283 Tebuconazole 35202779 Miranda, 2022 in vitro Mouse VCMs Ca2+ current "" IC50 33.2 25.800000000000004 40.60000000000000142108547152020037174224853515625 µM L-type calcium channel inhibitor 284 Tebuconazole 35202779 Miranda, 2022 in vitro Mouse VCMs K+ current "" IC50 5.7 4.2 7.20000000000000017763568394002504646778106689453125 µM IK potassium current inhibition 285 Telmisartan 23073892 Kim, 2012 in vitro Rat isolated heart Infarction size "" EC50 48.1 "" µM "" 286 Telmisartan 18664324 Tu, 2008 in vitro Oocytes hKv1.5 "" IC50 2.25 1.28 3.220000000000000195399252334027551114559173583984375 µM Peak current 287 Telmisartan 18664324 Tu, 2008 in vitro Oocytes hERG "" IC50 24.35 19.29 29.410000000000000142108547152020037174224853515625 µM "" 288 Telmisartan 18664324 Tu, 2008 in vitro Oocytes hKv1.5 "" IC50 0.82 0.43 1.20999999999999996447286321199499070644378662109375 µM 1.5 second end-pulse current 289 Tributyl phosphate (TBP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 66.5 "" µM "" 290 Triethyl phosphate (TEP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 6820.0 "" µM "" 291 Triphenyl phosphate (TPhP) 28259702 Sirenko, 2017 in vitro hiPSC-CMs Cell viability 24h 1 SD from control mean 10.05 "" µM Point of departure: one standard deviation difference in viable cell count from control mean. 292 Triphenyl phosphate (TPhP) 28259702 Sirenko, 2017 in vitro hiPSC-CMs Mitochondrial dysfunction 30m 1 SD from control mean 0.682448714400104 "" µM Point of departure: one standard deviation difference in granule intensity (JC-10) from control mean. 293 Triphenyl phosphate (TPhP) 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 30m 1 SD from control mean 1.9162149312627903 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 294 Triphenyl phosphate (TPhP) 28259702 Sirenko, 2017 in vitro hiPSC-CMs Peak frequency (beats per minute) 24h 1 SD from control mean 18.377242139483506 "" µM Point of departure: one standard deviation difference in peak frequency (BPM) from control mean. 295 Triphenyl phosphate (TPhP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 1.97 "" µM "" 296 Tripropyl phosphate (TPrP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 933.0 "" µM "" 297 Tris-(1,3-dichloro-2-propyl) phosphate (TDCPP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 3.83 "" µM "" 298 Tris-(2-butoxyethyl) phosphate (TBEP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 10.3 "" µM "" 299 Tris-(2-chloroethyl) phosphate (TCEP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 626.0 "" µM "" 300 Tris-(2-chloropropyl) phosphate (TCPP) 25661707 Du, 2015 in vivo Zebrafish Pericardium effusion 96h EC50 69.5 "" µM "" 301 Verapamil 22972846 Sirenko, 2013 in vitro hiPSC-CMs Beat rate "" IC50 0.055 "" µM "" 302 Verapamil 25237062 Scott, 2014 in vitro hiPSC-CMs Peak amplitude "" IC50 7.25 "" µM Decrease in amplitude 303 Verapamil 25237062 Scott, 2014 in vitro hiPSC-CMs Beat rate "" IC50 7.44 "" µM "" 304 Verapamil 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ current "" IC50 0.32 "" µM L-type calcium channel inhibitor 305 Verapamil 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ peak count "" IC50 0.315762326666667 0.1 0.64000000000000001332267629550187848508358001708984375 µM Peak count: number of contractions over a period of time. 306 Verapamil 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient width "" IC50 0.07754059017887538 0.01 0.13000000000000000444089209850062616169452667236328125 µM Width of the calcium transient 307 Verapamil 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient amplitude "" IC50 0.0212289733333333 0.01 0.0299999999999999988897769753748434595763683319091796875 µM Peak amplitude of the calcium peak as measurement for contractility 308 Verapamil 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient rise time "" IC50 0.13900017643224588 0.01 0.200000000000000011102230246251565404236316680908203125 µM "" 309 Verapamil 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient decay time "" IC50 0.0349676443728653 0.02 0.040000000000000000832667268468867405317723751068115234375 µM "" 310 Verapamil 25538221 Pointon, 2015 in vitro hiPSC-CMs Ca2+ transient spacing "" IC50 0.019115175830544666 0.01 0.0299999999999999988897769753748434595763683319091796875 µM "" 311 Verapamil 26983082 Gossmann, 2016 in vitro hiPSC-CMs Peak amplitude "" IC50 150.0 "" µM Peak amplitude of the contraction peak. 312 Verapamil 28069985 Pointon, 2017 in vitro 3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs) Peak amplitude "" IC50 5.16 2.02 13.0999999999999996447286321199499070644378662109375 µM Peak amplitude of the contraction peak. 313 Verapamil 28069985 Pointon, 2017 in vitro 3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs) Peak count "" IC50 0.1690375987746757 0.15883350098270407 42 µM Peak count: number of contractions over a period of time. 314 Verapamil 33078833 Blanchette, 2020 in vitro hiPSC-CMs Cell viability 90 min TDVF05 5.87 2.19 26.60000000000000142108547152020037174224853515625 42 TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported. 315 Verapamil 21328588 Mandenius, 2011 in vitro HL-1 Respiration "" EC50 32.0 31.0 36 µM "" 316 Verapamil 24585781 Stoehr, 2014 in vitro Cardiac construct, hiPSC Contractility "" IC50 968.1 "" nM "" 317 Verapamil 24052561 Guo, 2013 in vitro hiPSC-CMs Arrhythmia "" IB20 > 30  "" µM Lowest dose that induced =>20% arrhythmic beats in 3 consecutive 20s sweeps. 318 Verapamil 24052561 Guo, 2013 in vitro hiPSC-CMs Beat rate "" BR20 (↑) 0.03  "" µM Lowest dose that induced a reduction in beat rate of =>20% at 3 consecutive sweeps compared with control.